Zydus Lifesciences Ltd logo

Zydus Lifesciences Ltd

ZYDUSLIFE NSE

Key Fundamentals

MidcapPharmaceuticalsHealthcare
Market Cap
1.1L Cr
Volatility
Moderate
P/E Ratio
24.86
EBITDA
₹8,985 Cr
Return on Equity
16.99%
Debt to Equity
0.46
Book Value
₹271.78
EPS
₹41.43
52W High
₹1,205
52W Low
₹835.5

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Zydus Lifesciences Ltd insights

46 extracted metrics + investor summaries across FY05–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

1
  • Company has delivered good profit growth of 18.8% CAGR over last 5 years

Growth Rate

Revenue Growth
17.64% ↗
Net Income Growth
8.92% ↗
Cash Flow Change
-68.79% ↘
ROE
-2.97% ↗
ROCE
-12.51% ↗
EBITDA Margin (Avg.)
4.20% ↗

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 5d ago
AI opinion · based on fundamentals
Risk medium

Zydus Lifesciences is a ₹1.17 lakh crore market-cap Indian pharma company trading at a PE of 25.6x, with FY26 consolidated revenue of ₹27,148 crore (up 17% YoY) and adjusted net profit of ₹5,456 crore (up 15% YoY). The company has delivered consistent 21% ROE over 3, 5, and 10-year periods but faces near-term margin pressure, with Q1 FY27 EBITDA margin compressing 770 bps YoY to 24.1%.

Bull Case 8
  • Consistent revenue growth with FY26 revenue at ₹27,148 crore, up 17% YoY, and a 3-year compounded sales CAGR of 16%
  • Strong profitability track record with 3-year compounded profit CAGR of 32% and 5-year profit CAGR of 18.8%
  • Steady ROE of 21% maintained consistently across 3-year, 5-year, and 10-year periods indicating efficient capital deployment
  • Net cash balance sheet with net debt-to-equity ratio of negative 0.20x as of March 2025, providing financial flexibility for acquisitions and R&D
  • North America business grew 16% YoY in Q3 FY26 driven by volume expansion and new product launches, with saroglitazar targeting $200 million peak US sales post-FY28 launch
  • India branded formulations grew 20% YoY in Q1 FY27, outperforming the domestic pharma market, with strength across cardiology, diabetology, and oncology
  • Consumer wellness segment revenue surged 67% YoY in Q1 FY27, diversifying revenue beyond pure pharma
  • Stock has delivered 25% return over 1 year and 22% CAGR over 3 years, reflecting market confidence in execution
Bear Case 8
  • Significant margin compression in Q1 FY27 with EBITDA margin falling 770 bps YoY from 31.8% to 24.1%, raising sustainability concerns
  • Q1 FY27 net profit fell 36% YoY to ₹940 crore despite 22% revenue growth, indicating cost pressures outpacing topline gains
  • TTM compounded profit growth has decelerated sharply to just 5% versus the 3-year CAGR of 32%, suggesting earnings momentum is fading
  • PE of 25.6x is elevated for a company with decelerating profit growth of 5% TTM, implying limited margin of safety
  • Dividend yield of only 0.08% offers negligible income return to shareholders despite strong free cash flows
  • R&D spend at 8.1% of revenues (₹15,750 million for 9M FY26) is necessary but creates ongoing cost pressure with uncertain payoff timelines on novel assets
  • US generics business faces ongoing price erosion and litigation risks as flagged in company guidance, potentially capping upside in the largest revenue segment
  • Zydus Wellness integration expenses contributed to group-level profit decline, with the wellness subsidiary's net profit dropping 47% in FY26

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 18h ago
Headwinds 2
  • Q1 profit drops 35% YoY Aug 11

    Consolidated net profit fell 35% YoY to ₹9,398 crore in Q1FY27 due to exceptional items, though revenue grew 22% to ₹80,170 crore.

  • ₹108.54 mn stamp duty demand Jul 29

    Gujarat authorities issued a ₹108.54 million stamp duty demand over the Sterling Biotech asset acquisition, citing valuation differences and incomplete registration details.

Positives 3
  • Alvelestat licensing deal signed Aug 11

    Subsidiary Sentynl Therapeutics signed an option and license agreement with Mereo BioPharma for alvelestat in AATD-LD, with Mereo receiving up to $40 million in payments.

  • USFDA nod with CGT exclusivity Aug 4

    Secured final USFDA approval for Indocyanine Green for Injection with 180-day CGT exclusivity, targeting a $125.8 million US market. Adds to 445 cumulative US approvals.

  • Branded portfolio to drive revenue Aug 12

    Management expects branded portfolio to contribute over two-thirds of revenue, with US business growing from 10% to 15% by fiscal year end. Assertio to add $15-20 million quarterly starting next quarter.

Neutral 4
  • Investor roadshow in Asia Aug 17

    Non-deal roadshow scheduled in Singapore and Hong Kong from August 24-26, 2026, disclosed by Company Secretary Dhaval N. Soni.

  • Multiple investor conference appearances Aug 4

    Zydus participating in Motilal Oswal (Aug 18), Emkay Confluence 2026 (Aug 13), and Equirus Annual India Conference (Aug 13) to engage institutional and retail investors.

  • Ahmedabad ops resumed after rains Jul 25

    Operations at Ahmedabad facilities temporarily suspended due to heavy rains and waterlogging were confirmed resumed on July 25, 2026.

  • Q1 FY27 board meeting and call Jul 30

    Board meeting held August 11 to consider Q1 FY27 results, with Dr. Sharvil Patel hosting the post-results webinar at 4:00 PM IST.

TL;DR: Zydus Lifesciences is executing well on its branded portfolio and US generics pipeline, with a strong new USFDA approval and a licensing deal adding near-term value. The 35% profit decline is optically concerning but driven by exceptional items rather than operational weakness, while revenue grew 22% YoY. The stamp duty demand is a minor regulatory overhang. The trend is constructive with multiple growth levers (Assertio contribution, branded margins targeting 28-30%+), though investors should monitor exceptional item clarity in coming quarters.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
5,140
4,369
4,505
5,534
6,208
5,237
5,269
6,528
6,574
6,123
6,864
7,587
8,017
Expenses
3,634
3,223
3,403
3,903
4,124
3,776
3,882
4,402
4,485
4,107
5,048
5,033
6,088
Operating Profit
1,505
1,146
1,102
1,630
2,084
1,461
1,388
2,126
2,088
2,016
1,816
2,554
1,929
OPM %
29%
26%
24%
29%
34%
28%
26%
33%
32%
33%
26%
34%
24%
Other Income
21
53
60
160
63
68
57
-139
155
75
26
-263
88
Interest
18
9
20
35
32
25
32
77
85
101
130
123
156
Depreciation
180
184
195
205
215
234
229
238
238
302
360
508
555
PBT
1,328
1,006
947
1,550
1,900
1,271
1,184
1,672
1,921
1,687
1,353
1,660
1,307
Tax %
16%
22%
23%
21%
23%
29%
15%
25%
23%
27%
29%
19%
27%
Net Profit
1,134
803
790
1,246
1,482
920
1,026
1,244
1,521
1,239
1,023
1,341
990
EPS in Rs
10.74
7.91
7.8
11.75
14.11
9.06
10.17
11.64
14.58
12.51
10.36
12.65
9.42
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
8,651
9,427
9,376
11,905
13,166
14,253
15,102
15,265
17,237
19,547
23,242
27,148
28,592
Expenses
6,896
7,095
7,474
9,074
10,174
11,455
11,758
11,923
13,378
14,163
16,183
18,673
20,276
Operating Profit
1,756
2,332
1,902
2,831
2,991
2,798
3,344
3,342
3,860
5,384
7,058
8,475
8,316
OPM %
20%
25%
20%
24%
23%
20%
22%
22%
22%
28%
30%
31%
29%
Other Income
45
112
127
111
183
-264
-171
2,581
-422
293
50
-7
-74
Interest
68
53
45
91
194
342
164
127
130
81
166
439
510
Depreciation
287
292
373
539
599
696
725
713
723
764
916
1,408
1,725
PBT
1,446
2,099
1,612
2,312
2,382
1,495
2,285
5,084
2,585
4,832
6,027
6,621
6,007
Tax %
18%
8%
8%
24%
22%
21%
6%
10%
23%
20%
23%
24%
—
Net Profit
1,188
1,964
1,517
1,810
1,899
1,204
2,185
4,618
2,092
3,973
4,673
5,124
4,593
EPS in Rs
11.24
18.89
14.53
17.35
18.06
11.49
20.84
43.83
19.37
38.36
44.97
50.09
44.94
Div. Payout %
21%
17%
22%
20%
19%
30%
17%
6%
31%
8%
24%
2%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
102
102
102
102
102
102
102
102
101
101
101
101
Reserves
4,149
5,597
6,858
8,642
10,284
10,273
12,890
16,897
17,415
19,729
23,852
27,011
Borrowings
2,651
2,442
5,207
5,407
7,899
7,986
4,584
4,221
1,195
804
3,213
12,496
Other Liabilities
2,144
2,208
2,937
3,632
4,945
5,115
6,189
6,421
6,851
8,201
9,523
11,065
Total Liabilities
9,047
10,350
15,104
17,783
23,231
23,477
23,765
27,642
25,562
28,834
36,689
50,673
Fixed Assets
3,352
3,748
5,755
6,483
12,164
12,230
12,133
12,253
11,521
12,368
13,134
24,106
CWIP
798
951
1,543
1,527
837
742
783
661
1,201
2,423
2,692
3,698
Investments
154
416
435
746
674
765
830
3,288
1,547
1,220
6,412
7,540
Other Assets
4,743
5,235
7,371
9,028
9,556
9,740
10,019
11,439
11,294
12,822
14,451
15,328
Total Assets
9,047
10,350
15,104
17,783
23,231
23,477
23,765
27,642
25,562
28,834
36,689
50,673
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
994
1,894
1,312
919
1,282
2,505
3,293
2,104
2,689
3,228
6,781
2,117
Investing
-465
-860
-2,872
-974
-3,977
-1,012
-835
1,137
1,178
-1,492
-8,363
-7,895
Financing
-351
-935
2,316
52
1,885
-1,094
-2,549
-868
-4,400
-1,810
1,995
5,807
Net Cash Flow
178
99
756
-3
-811
399
-90
2,373
-534
-75
414
28
Free Cash Flow
498
936
-1,623
-116
236
1,617
2,446
1,050
1,697
2,345
5,139
-530
CFO/OP
79
109
81
54
65
100
109
83
85
84
122
44
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
67
68
89
98
110
94
76
80
94
97
64
73
Inventory Days
175
158
193
211
208
207
227
245
197
202
227
282
Days Payable
125
154
165
167
149
151
155
141
123
125
131
142
Cash Conversion Cycle
118
71
116
142
169
150
148
184
168
175
160
212
Working Capital Days
6
-1
-34
17
10
-19
-6
19
70
88
3
-40
ROCE %
23%
28%
16%
18%
15%
11%
14%
13%
15%
22%
24%
21%

Shareholding Pattern

As of Jun 2026
Promoters 75.01%
DIIs 11.27%
FIIs 6.88%
Public 5.45%
Others 1.38%
Total 99.99%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
74.88%
74.88%
74.88%
74.88%
74.88%
74.88%
74.98%
74.98%
74.98%
74.98%
74.98%
74.98%
74.98%
74.98%
74.98%
74.98%
74.99%
74.99%
74.99%
75.00%
75.00%
75.01%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
5.72%
5.59%
7.52%
7.53%
7.32%
7.13%
7.34%
7.06%
6.95%
6.88%
DIIs
11.11%
10.43%
11.22%
11.78%
12.78%
11.92%
12.94%
13.69%
13.60%
13.23%
13.09%
12.79%
12.63%
12.64%
10.65%
10.65%
11.01%
11.13%
10.86%
11.09%
11.20%
11.27%
Government
0.19%
0.07%
0.07%
0.07%
0.08%
0.08%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
6.16%
7.31%
7.38%
7.40%
7.81%
8.02%
7.60%
7.04%
6.42%
5.97%
5.67%
5.60%
5.29%
5.37%
5.48%
5.47%
5.41%
5.46%
5.49%
5.54%
5.54%
5.45%
Others
7.66%
7.32%
6.44%
5.87%
4.46%
5.11%
4.48%
4.29%
5.00%
5.82%
6.26%
6.63%
1.38%
1.43%
1.37%
1.36%
1.28%
1.28%
1.32%
1.31%
1.32%
1.38%
No. of Shareholders
0
2,23,384
3,31,155
3,51,595
3,70,931
4,08,017
4,55,624
4,08,231
3,70,396
3,11,764
2,97,953
3,06,495
2,94,324
3,36,309
3,70,863
3,65,356
3,71,619
3,86,127
3,96,105
4,03,266
4,18,314
4,03,889

Documents

Frequently Asked Questions about Zydus Lifesciences Ltd

What does Zydus Lifesciences Ltd do?
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise...
Where is Zydus Lifesciences Ltd (ZYDUSLIFE) listed?
Zydus Lifesciences Ltd is listed on the Indian stock exchanges. It is listed on NSE: ZYDUSLIFE and BSE: 532321. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Zydus Lifesciences Ltd belong to?
Zydus Lifesciences Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd has a market capitalisation of approximately ₹114348.43 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Zydus Lifesciences Ltd?
The Price-to-Earnings (PE) ratio of Zydus Lifesciences Ltd is 24.86. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Zydus Lifesciences Ltd?
Over the past 52 weeks, Zydus Lifesciences Ltd has traded between a low of ₹835.5 and a high of ₹1,205. This range helps investors understand the stock's price volatility and recent trading levels.
Does Zydus Lifesciences Ltd pay dividends?
Yes, Zydus Lifesciences Ltd has a dividend yield of 0.09%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd has a Return on Equity (ROE) of 16.99%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Zydus Lifesciences Ltd on Tapetide?
On Tapetide, you can view Zydus Lifesciences Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe

Website zyduscadila.com
CEO Dr. Sharvil Pankajbhai Patel
Employees 27,917
Listed 2000-04-18
Face Value ₹ 1
Issued Size 1,00,62,33,990

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List